珠海润都制药股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 珠海润都制药股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 12 月 03 日上午 10:00 以现场结合通讯表决的方式召开，会议通知 以电子邮件的方式于 2025 年 11 月 28 日向各位董事发出。会议应到董事 8 人， 实到董事 8 人（其中 LIAORAN 先生、由春燕女士、王波先生、叶建木先生、胡正 喜先生以通讯表决的形式出席本次会议）。公司高级管理人员列席了本次会议， 本次会议由公司董事长陈新民先生主持，会议召集及召开程序符合《中华人民共 和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过了《关于公司及子公司向商业银行申请综合授信及贷款的议案》。 证券代码：002923 证券简称：润都股份 公告编号：2025-056 上述担保额度尚未拟定具体协议。提请公司股东会同意董事会授权公司法定 代表人或其指定的授权代理人代表公司办理相关手续，签署上述担保额度内的相 关法律文 ...

证券代码：002923 证券简称：润都股份 公告编号：2025-057 向银行申请的授信业务范围包括但不限于流动资金贷款、非流动资金贷款、 承兑汇票、保函、开立信用证等业务。 公司及子公司2026年度向上述银行申请的授信额度总计为人民币25亿元整 （最终以银行实际审批的授信额度为准），具体融资金额将视公司及子公司项目 建设和运营资金的实际需求来确定，且不超过上述具体授信金额；可根据与各银 行的协商情况适时调整在各银行的融资金额、融资类型、融资费用及融资期限等 具体事项，并签署相关业务合同及其它相关法律文件。 同时提请公司股东会同意董事会授权公司及子公司法定代表人或其指定的 授权代理人代表公司办理相关手续，签署上述授信额度内的一切授信（包括但不 限于授信、借款、担保、抵押、融资、信托、租赁、银行承兑汇票、国内信用证 等）有关的合同、协议、凭证等各项法律文件。 本议案尚须提交股东会审议通过后方可实施，授权期限为：自股东会审议通 过之日起十二个月。在上述授权期限及额度范围内，综合授信额度可循环使用。 二、相关审批程序 1、董事会决议情况 珠海润都制药股份有限公司 关于公司及子公司向商业银行申请综合授信及贷款的公告 ...

证券代码：002923 证券简称：润都股份 公告编号：2025-058 珠海润都制药股份有限公司 关于 2026 年度为全资子公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 本次担保后，公司为合并报表范围内的子公司提供担保额度总金额为 122,810万元，超过最近一期经审计净资产100%，公司为合并报表范围内资产负 债率超过70%的子公司提供担保额度金额为121,160万元，超过公司最近一期经审 计净资产100%。敬请投资者注意相关风险。 重要内容提示： 被担保人名称及是否为上市公司关联人： 被担保人润都制药（荆门）有限公司（以下简称"润都荆门公司"）为珠海 润都制药股份有限公司（以下简称"公司"或"润都股份"）的全资子公司，不 属于润都股份的关联人。 上市公司及控股子公司对外担保总额占最近一期经审计净资产比例: 本次担保后，预计上市公司及其控股子公司的担保额度总计不超过122,810 万元，约占上市公司最近一期经审计净资产的比例为106.60%。 公司预计未来12个月为润都荆门公司新增担保额度总计不超过20,000 ...

证券代码：002923 证券简称：润都股份 公告编号：2025-059 珠海润都制药股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、股东会召开日期：2025 年 12 月 19 日（星期五） 2、本次股东会采用的网络投票系统：深圳证券交易所交易系统、深圳证 券交易所互联网投票系统 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 公司第五届董事会第十六次会议审议通过《关于召开 2025 年第三次临时 股东会的议案》，同意召开本次股东会。 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 12 月 19 日（星期五）14:30 开始； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体 时 ...

青蒿素概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 600267 | 海正药 业 | 2.49 | 1.25 | 299.33 | 1.88 | | 600196 | 复星医 药 | -0.15 | 0.38 | 177.88 | 0.82 | | 600422 | 昆药集 团 | 0.30 | 0.39 | 140.40 | 3.59 | | 002923 | 润都股 份 | -0.50 | 1.47 | -235.00 | -4.49 | | 600216 | 浙江医 药 | -0.07 | 0.49 | -350.82 | -5.28 | | 600062 | 华润双 鹤 | 0.75 | 0.51 | -801.15 | -8.02 | | 002001 | 新和成 | 0.21 | 0.58 | -817.72 | -1.88 | | 600721 | 百花医 药 | -2.20 | 4.59 ...

Core Points - The company, Rundu Co., Ltd. (002923.SZ), announced on November 28 that the share reduction by its common actual controller, Mr. Li Xi, is based on personal funding needs and has complied with relevant regulations regarding information disclosure [2] Group 1: Shareholder Actions - The share reduction by Mr. Li Xi has been conducted in accordance with the "Interim Measures for the Administration of Share Reduction by Shareholders of Listed Companies" [2] - The company has disclosed the details of the share reduction in its announcement on the Giant Tide Information Network [2] Group 2: Regulatory Compliance - The company is adhering to the "Regulations on the Suspension and Resumption of Review Time in the Drug Review Process" issued by the National Medical Products Administration [2] - The review status of the drug, Sodium Deoxycorticosterone Injection, has been changed to suspended, but it remains in the review phase, which is considered normal [2] Group 3: Future Disclosure - The company commits to timely information disclosure in case of any significant developments regarding the drug review process [2]

Core Insights - The article highlights a trend of decreasing shareholder accounts among 759 companies, indicating a concentration of shares. Notably, 87 companies have seen a decline in shareholder accounts for more than three consecutive periods, with some experiencing a drop for up to ten periods [1][2]. Group 1: Shareholder Account Trends - 87 companies have reported a continuous decrease in shareholder accounts for over three periods, with some like Rundu Co. and Mingpai Jewelry seeing declines for ten periods, with reductions of 38.45% and 30.49% respectively [1]. - Companies with significant recent declines in shareholder accounts include Duoli Technology, Laimei Pharmaceutical, and Three Gorges Tourism, with decreases of 13.93%, 12.56%, and 12.18% respectively [1][2]. Group 2: Market Performance - Among the companies with declining shareholder accounts, 26 have seen their stock prices rise, while 61 have experienced declines. Notable gainers include Allianz Vision, Ximai Food, and Luoping Zinc, with increases of 36.65%, 27.81%, and 23.19% respectively [2]. - 26 companies have outperformed the Shanghai Composite Index during this period, representing 29.89% of the group, with Allianz Vision, Ximai Food, and Luoping Zinc achieving relative returns of 35.49%, 28.65%, and 23.67% respectively [2]. Group 3: Industry and Institutional Interest - The industries with the highest concentration of companies experiencing declining shareholder accounts include machinery, automotive, and basic chemicals, with 12, 8, and 6 companies respectively [2]. - In terms of institutional interest, 14 companies with declining shareholder accounts were surveyed by institutions in the past month, with frequent surveys for companies like Boying Special Welding and China Resources Materials [2].

Group 1 - The Artemisinin concept index rose by 0.31%, ranking 10th among concept sectors, with three stocks increasing in value, including Delong Huineng, Rundu Co., and Haizheng Pharmaceutical, which rose by 4.35%, 0.87%, and 0.19% respectively [1] - The leading decliners in the sector included Fosun Pharma, New Hecheng, and Baiyunshan, which fell by 1.23%, 0.36%, and 0.34% respectively [1] Group 2 - The main capital flow analysis indicates a net outflow of 176 million yuan from the Artemisinin concept sector, with only one stock, Delong Huineng, experiencing a net inflow of 8.0428 million yuan [2] - The capital flow rankings for the Artemisinin concept show that Delong Huineng had a trading volume of 4.35% and a turnover rate of 13.19%, while other stocks like Kunming Pharmaceutical Group and Rundu Co. had net outflows of 1.72 million yuan and 3.06 million yuan respectively [2][3]

Core Insights - The company, Rundu Co., Ltd. (002923), reported that as of November 10, 2025, it will have a total of 22,516 households [1] Summary by Categories - **Company Information** - Rundu Co., Ltd. has confirmed a total of 22,516 households as of the specified date [1]

Core Viewpoint - The company, Rundu Co., has indicated that its sales of Rabeprazole Sodium Enteric-coated Capsules will significantly decline in 2024 due to the impact of the ninth batch of national drug procurement, which will adversely affect its performance in 2024 and the first half of 2025 [1] Group 1 - The sales volume of Rabeprazole Sodium Enteric-coated Capsules is expected to drop substantially in 2024 [1] - The performance impact is anticipated to be significant for both 2024 and the first half of 2025 [1] - By the third quarter of 2025, sales of the product are projected to be roughly in line with the same period last year [1] Group 2 - The company highlights the good clinical efficacy and market reputation of the product, suggesting a potential recovery in market size in the future [1]